Beijing Lunarsun Pharmaceutical

Beijing Lunarsun Pharmaceutical Co., Ltd., also known as Lairuisen Pharma, is a prominent Chinese pharmaceutical company specializing in the research, development, and global distribution of generic drugs, active pharmaceutical ingredients (APIs), and intermediates. Founded in 2006 and headquartered in Beijing, the company operates using a Marketing Authorization Holder (MAH) model, focusing its internal efforts on R&D and marketing while leveraging subsidiaries and partners for manufacturing. Lunarsun holds over 100 drug certificates and has filed more than 50 APIs, covering critical therapeutic areas such as oncology, anti-infectives, cardiovascular diseases, and metabolic disorders. The company maintains a robust international trade network, exporting to major markets including the United States, the European Union, and India, and provides specialized services in import registration and distribution for foreign pharmaceutical entities entering China. With a dedicated research institute in Beijing and manufacturing capabilities in Chongqing and Jiangsu, Lunarsun is a key player in the globalization of the Chinese pharmaceutical industry.